N6-methyladenine-modified DNA was decreased in Alzheimer’s disease patients

doi:10.12998/wjcc.v10.i2.448

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 2

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4242)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-1) series.

Item

Count

PDF

195

WORD

HTML

2104

Figures (1-3)

233

Tables (1-1)

236

Sum=2821

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

222

Download

517

Sum=739

Publishing Process of This Article

Item

Count

Browse

225

Download

457

Sum=682

Jan 14, 2022 (publication date) through Aug 25, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Cases. Jan 14, 2022; 10(2): 448-457
Published online Jan 14, 2022. doi: 10.12998/wjcc.v10.i2.448

Full Size Figure Download Figure

Figure 1 Global N6-methyladenine DNA level in peripheral blood samples from 179 Alzheimer’s disease patients and 147 normal controls. AD: Alzheimer’s disease; NC: Normal control.

Citation: Lv S, Zhou X, Li YM, Yang T, Zhang SJ, Wang Y, Jia SH, Peng DT. N6-methyladenine-modified DNA was decreased in Alzheimer’s disease patients. World J Clin Cases 2022; 10(2): 448-457
URL: https://www.wjgnet.com/2307-8960/full/v10/i2/448.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i2.448